Trilobio Secures $8 Million Funding to Revolutionize Biologist Work with Whole Lab Automation SAN FRANCISCO — Trilobio, a company developing fully automated robotic labs for biologists, announced today that it has secured an $8 million seed investment. The round, which was oversubscribed, was led by Initialized Capital and included contributions from Argon Ventures and Lowercarbon Capital. Founded in 2021, Trilobio aims to tackle longstanding issues of data quality and reproducibility that hinder research efficiency. It is estimated that 77% of biologists struggle to reproduce experimental results, leading to wasted time and resources. The new funding will enable Trilobio to expand its team, accelerate product development, and bring its innovative lab automation solutions to market faster. The company’s flagship product, dubbed "lab-in-a-box," is a compact, fully automated system designed to streamline complex biological experiments. By integrating advanced robotics and artificial intelligence, Trilobio's solution can perform tasks with greater precision and consistency than human researchers, significantly enhancing the reliability and repeatability of scientific data. Dr. Emily Carter, CEO of Trilobio, emphasized the importance of this technology in advancing biological research. "Our goal is to empower scientists by eliminating the tedious and error-prone aspects of lab work," she said. "With our automated systems, researchers can focus on high-level thinking and innovation, knowing that the data they generate is both robust and reproducible." One of the primary challenges in biological research is the variability introduced by manual lab processes. Human error, subtle differences in technique, and fluctuations in environmental conditions can all contribute to inconsistent results. Automated systems, like those developed by Trilobio, help mitigate these factors by standardizing procedures and maintaining controlled environments. The impact of such automation is expected to be significant. In addition to improving data quality, automated labs can increase throughput, reduce costs, and free researchers to pursue more ambitious projects. This is particularly important in fields such as pharmaceuticals, where the ability to quickly and accurately test large numbers of compounds can speed up drug discovery and development. Initialized Capital, known for backing early-stage startups with transformative potential, sees great promise in Trilobio's approach. "Biological research has long been plagued by issues of reproducibility and efficiency," stated Garry Tan, managing partner at Initialized Capital. "Trilobio's innovative solution could revolutionize how experiments are conducted, leading to more consistent and reliable results. We are thrilled to support them in this endeavor." Lowercarbon Capital, a venture firm focused on climate solutions, also highlighted the sustainability benefits of Trilobio's technology. "By reducing the need for repeated experiments and minimizing resource waste, Trilobio's automated labs have the potential to lower the carbon footprint associated with biological research," noted Chris Sacca, founder of Lowercarbon Capital. Trilobio's lab-in-a-box system is currently being piloted at several leading research institutions. Early feedback has been positive, with scientists praising the system's ease of use and the significant time savings it offers. The company plans to finalize the product and begin commercial sales by the end of 2023. As the demand for high-quality, reproducible biological data continues to grow, Trilobio is well-positioned to meet this need. Its automated lab solutions promise to not only improve the efficiency and accuracy of research but also to foster a more sustainable and productive scientific environment. With the support of top-tier investors, Trilobio is poised to make a substantial impact in the field of biology and beyond.